What Is The Predicted Revenue Outlook For The Global Locally Advanced Pancreatic Cancer Market To Surpass $1.56 Billion?
Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
What Is The Projected Valuation Of The Locally Advanced Pancreatic Cancer Market In The Coming Years?
The market size for locally advanced pancreatic cancer has recently witnessed swift expansion. It is anticipated to increase from $0.95 billion in 2024 to $1.05 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 10.6%. The historical growth in this sector can be credited to a heightened awareness about pancreatic cancer, advancements in chemotherapy processes, increased utilisation of targeted therapies, escalating incidence of pancreatic cancer, the evolution of combination treatment methodologies, and bettered options for supportive care.
In the upcoming years, rapid expansion is projected for the locally advanced pancreatic cancer market, with forecasts indicating a growth to $1.56 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 10.4%. Contributing factors for this predicted growth include heightened awareness about pancreatic cancer, betterments in chemotherapy regimens, increased application of targeted therapies, a surge in pancreatic cancer cases, introduction of combination treatment methods, and improved supportive care alternatives. During the forecasted period, the main trends to influence the market include the progress in immunotherapy, the evolution of targeted therapies, refinement of precision radiation strategies, enhancement of diagnostic imaging, inclination towards minimally invasive surgeries, application of artificial intelligence in devising treatment strategies, and advancements in combination therapy.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21214&type=smp
Which Market Dynamics Are Playing A Critical Role In The Growth Of The Locally Advanced Pancreatic Cancer Market?
The rise in the usage of tobacco is anticipated to fuel the expansion of the marketplace for locally advanced pancreatic cancer. Tobacco, a plant whose leaves form the basis of products like cigarettes and cigars, contains an addictive substance, nicotine. This substance is associated with grave health problems including cancer and heart disease. The surge in tobacco usage is propelled by factors including easy availability, low-cost, advertising of tobacco products, societal endorsement in some regions, and stress-induced smoking. The use of tobacco is a substantial risk component in the formation of locally advanced pancreatic cancer, leading to a higher occurrence of pancreatic cancers. For instance, the Global Action to End Smoking, an American not-for-profit organization focusing on research to curb the smoking crisis, reported in January 2024 that an estimated 62.9 million adults in the U.S. were tobacco users in 2022. This figure placed the U.S. 4th globally and 1st in the Americas in terms of tobacco consumption. They also noted that around 11.5% of American adults (roughly 28.3 million people) were cigarette smokers and the percentage was higher in males (13.1%) as compared to females (10.1%). Thus, the escalation in tobacco use is a key factor propelling the growth of the locally advanced pancreatic cancer industry.
Which Sub-Segments Are Driving Growth Within The Locally Advanced Pancreatic Cancer Market?
The locally advanced pancreatic cancermarket covered in this report is segmented –
1) By Therapy: Chemotherapy; Immunotherapy; Radiation Therapy; Surgery
2) By Route Of Administration: Oral; Injectables; Other Route Of Administrations
3) By End-User: Hospital; Specialty Clinics; Research Institutions; Other End-Users
Subsegments:
1) By Chemotherapy: Gemcitabine-based Chemotherapy; FOLFIRINOX Chemotherapy
2) By Immunotherapy: Immune Checkpoint Inhibitors; Cancer Vaccines
3) By Radiation Therapy: External Beam Radiation Therapy; Stereotactic Body Radiation Therapy (SBRT)
4) By Surgery: Pancreaticoduodenectomy (Whipple Procedure); Distal Pancreatectomy; Total Pancreatectomy
What Key Trends Are Driving Growth In The Locally Advanced Pancreatic Cancer Market?
Companies in the locally advanced pancreatic cancer market are turning to orphan drug development to improve therapy choices and meet the needs of patients with this aggressive disease. Orphan drugs are aimed at treating rare conditions and are supported by incentives like tax benefits and market exclusivity. In January 2025, US-based Actuate Therapeutics Inc. announced that its GSK-3ß inhibitor Elraglusib had received Orphan Drug Designation from both the FDA and EMA for the treatment of pancreatic ductal adenocarcinoma (PDAC). This designation follows strong Phase 2 trial results, highlighting the drug’s promise in treating advanced PDAC.
Which Players Are Shaping The Competitive Landscape Of The Locally Advanced Pancreatic Cancer Market?
Major companies operating in the locally advanced pancreatic cancer market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck KGaA, AbbVie Inc., Bayer Inc., Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, Novartis AG, GSK plc, Ipsen Biopharmaceuticals Inc., Lupin Limited, NovoCure Limited, Theratechnologies Inc., XBiotech, Prestige Biopharma, OSE Immunotherapeutics, Helix Biopharma Corporation, Fawn Incorporation, Eli Lilly and Co
Access The Complete Report Here:
How Do Regional Dynamics Influence The Locally Advanced Pancreatic Cancer Market Performance?
North America was the largest region in the locally advanced pancreatic cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the locally advanced pancreatic cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=21214&type=smp
Browse Through More Reports Similar to the Global Locally Advanced Pancreatic Cancer Market 2025, By The Business Research Company
Pancreatic Cancer Drugs Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/pancreatic-cancer-drugs-global-market-report
Pancreatic Cancer Diagnostic Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/pancreatic-cancer-diagnostic-global-market-report
Exocrine Pancreatic Insufficiency Epi Therapeutics And Diagnostics Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
